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Odense M, DenmarkA B S T R A C TObjectives: To examine the heterogeneity in cost-effectiveness anal-
yses of patient-tailored complex interventions. Methods: Latent class
analysis (LCA) was performed on data from a randomized controlled
trial evaluating a patient-tailored case management strategy for
patients suffering from chronic obstructive pulmonary disease
(COPD). LCA was conducted on detailed process variables representing
service variation in the intervention group. Features of the identiﬁed
latent classes were compared for consistency with baseline demo-
graphic, clinical, and economic characteristics for each class. Classes
for the control group, corresponding to the identiﬁed latent classes for
the intervention group, were identiﬁed using multinomial logistic
regression. Cost-utility analyses were then conducted at the class
level, and uncertainty surrounding the point estimates was assessed
by probabilistic sensitivity analysis. Results: The LCA identiﬁed three
distinct classes: the psychologically care class, the extensive COPD
care class, and the limited COPD care class. Patient baseline character-
istics were in line with the features identiﬁed in the LCA. Evaluation
of cost-effectiveness revealed highly disparate results, and caseee front matter Copyright & 2018, International S
r Inc. This is an open access article under the CC
ons.org/licenses/by-nc-nd/4.0/).
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torgaardsoerensen@gmail.com.management for only the extensive COPD care class appeared cost-
effective with an incremental cost-effectiveness ratio of £26,986 per
quality-adjusted life-year gained using the threshold value set by the
National Institute of Health and Care Excellence. Conclusions: Find-
ings indicate that researchers evaluating patient-tailored complex
interventions need to address both supply-side variation and
demand-side heterogeneity to link ﬁndings with outcome. The article
speciﬁcally proposes the use of LCA because it is believed to have the
potential to enable more appropriate targeting of complex care
strategies.
Keywords: case management, chronic obstructive pulmonary disease,
complex interventions, economic evaluation, heterogeneity, latent
class analysis, variability.
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access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Health economic evaluation of complex interventions is still in its
infancy and needs to be developed further [1,2]. This article is a
contribution to this development.
Health economists evaluating complex interventions are faced
with a number of challenges, because complex interventions often 1)
consist of multiple components that act both on their own and in
conjunction with each other, 2) are provided to a group of patients
with different unobservable preferences and needs, and 3) are
studied in pragmatic trials in which the provided health care
typically varies over time and in patients and providers in contrast
to protocol-driven trials (e.g., drug-trials).
A standard health economic evaluation treats patients as a
homogeneous group, and the effects and costs of alternatives arecalculated and presented as average point estimates for the
group with a given uncertainty. Nevertheless, applying such an
approach for interventions containing heterogenic groups of
patients might lead to wrongful decisions of funding; for exam-
ple, an intervention reimbursed on the basis of its average cost-
effectiveness for the total population may not be cost-effective
for a subgroup of these patients. Health economists taking
patient heterogeneity into account typically stratify their analy-
ses according to traditional subgrouping methods. In such anal-
yses patient heterogeneity is assessed using either prespeciﬁed
subgroups or subgroups identiﬁed post hoc on the basis of
observable patient characteristics associated with outcome [3,4].
Such subgrouping methods are problematic though, when eval-
uating complex interventions entailing multiple components and
unobservable patient heterogeneity, because they do not addressociety for Pharmacoeconomics and Outcomes Research (ISPOR).
BY-NC-ND license
ent of Business and Management, Danish Center for Healthcare
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V A L U E I N H E A L T H 2 1 ( 2 0 1 8 ) 2 3 9 – 2 4 7240the actual differences in patient treatment pathways. Although
efforts have been made to guide those evaluating complex
interventions, practical advice on how to evaluate and report
on patient heterogeneity is described in less detail [1,2,5]. Hence,
previous studies of patient heterogeneity in complex interven-
tions have solely focused on reporting differences in frequencies
or duration [6,7].
In this article, we propose a new method for analyzing
heterogeneity in a randomized controlled trial (RCT) of a complex
intervention in health care. We will consider the case with a
single provider of health care services delivering a multicompo-
nent intervention to a single group of patients. Context and
implementation issues are not included although these issues
could probably also be taken into account. The sources of
complexity under these circumstances can then be reduced to
1. different types of care (i.e., the different components that the
intervention consists of);
2. different levels of intensity of treatment (i.e., the different
combinations of components that the individual patient may
receive and how much);
3. a selection process, postrandomization, into different types
and intensity of treatment (i.e., the selection of the “package”
or patient pathway for the individual patient). This selection
process is likely to be driven by patients’ needs and prefer-
ences (probably unobservable to the analyst and the decision
maker) as well as case manager preferences.
Given these treatment features, heterogeneity in treatment
efﬁcacy and costs may arise from
1. the type of care: one component of the care may be more cost-
effective in itself than other components, regardless of
patients’ characteristics;
2. the level of intensity of care (i.e., the number of treatment
components provided and how much may drive efﬁcacy and
costs regardless of the type of care);
3. the selection on returns: patients may respond better to some
type/intensity of treatment because of unobservable health
characteristics, preferences, or needs and may select them-
selves (or are selected by the health care provider) accordingly.
For simplicity, we will use the term “demand-side heteroge-
neity” to describe observable and unobservable patient character-
istics associated with heterogeneity in costs and efﬁcacy of
treatment. The term “supply-side variation” will be used to
describe the different types of care and different levels of
intensity of care provided to the patients.
As an alternative method to identify subgroups within a
heterogeneous sample/patient group, latent class analysis (LCA)
has been performed in this study. The method has widely been
applied in marketing research, in which it is used to classify
consumers into underlying segments with the purpose of max-
imizing within-segment homogeneity and between-segment het-
erogeneity according to similarities in response patterns [8]. In
LCA, unobserved latent variables are inferred from observed
measures usually on the basis of individual responses from
multivariate categorical data [9]. In the ﬁeld of health economics,
LCA has previously been used to examine unobserved patterns in
demand for, access to, and utilization of health care [10–13], and
to quantify patient preferences for treatment [14,15]. Neverthe-
less, to our knowledge, the use of LCA in the ﬁeld of health
economic evaluation is yet to be explored.
In this article, we propose the use of LCA not as a segmenta-
tion tool based on traditional customer/patient differences, but as
a tool for identifying patterns of interaction between supply-sidevariation and demand-side heterogeneity in the evaluation of
complex interventions. The method is illustrated using data from
a complex RCT of case management for patients suffering from
chronic obstructive pulmonary disease (COPD) [16,17]. The inter-
vention contained both supply-side variation and demand-side
heterogeneity, because the patients could receive different types
of care and at varying intensities in response to each individual’s
needs and preferences for care. The process of care selection was
conducted after randomization, and care was continuously
adjusted throughout the trial on the basis of changing health
status and patient preferences. This article focuses on demon-
strating the use of LCA as a tool for investigating service variation
and patient heterogeneity in cost-effectiveness analyses of com-
plex interventions. The purpose of the study was speciﬁcally to 1)
identify latent classes on the basis of different patterns of service
provision in the case management of COPD, 2) examine the
heterogeneity of patient characteristics of the identiﬁed classes,
and 3) estimate cost-effectiveness at the class level.Methods
The RCT was conducted in a large Danish municipality from 2012
to 2014. The study had an intervention period of 12 months and
included 150 patients with COPD. Patients were eligible for
participation if they had been referred by their general practi-
tioner or by hospital respiratory specialists for pulmonary reha-
bilitation at the local rehabilitation center in 2011. The patients
were randomly assigned to either an intervention group or a
control group. A thorough description of the study design can be
found elsewhere [16].
Control
Patients in the control group received usual care as according to
most recent evidence-based guidelines [18]. In the intervention
period, the control group had no contact with the case manager.
Intervention
Patients assigned to the intervention group received community-
based case management in addition to usual care, and the
program was delivered by an experienced COPD nurse. The case
manager was not supposed to take over the role and responsi-
bility of other health care providers but to serve as an advisor and
support person. The focus of the intervention was to develop and
support the autonomy and self-care of the patients so that the
patients would be better equipped to handle their disease. The
case manager used motivational dialogue and positive perform-
ance feedback in her work.
The intervention consisted of a total of eight components. All
patients were provided with the knowledge of COPD, its associ-
ated consequences, and advice on the incorporation of physical
activities in daily life. In addition, the patients were educated in
how to manage exacerbations; they were trained in correct
inhalation and coughing techniques, and they received an intro-
duction on why, when, and how to take their COPD medication
correctly. Advice on proper diet was provided, and smokers
received support for smoking cessation. The case manager
prepared the patients for appointments with other health pro-
fessionals through formulation of issues and questions to
address, and she provided general counseling and support
throughout the intervention. Tailored care plans were formulated
together with each patient on the basis of what was relevant for
the individual, and the health status and needs of each patient
were continuously monitored through regular telephone calls
and face-to-face meetings. The multicomponent nature of the
Table 1 – Overview of the components of the case
management intervention and associated rates
provided for the patients.
Intervention component Rate
Instructions on how to prevent, detect, and deal with
acute exacerbations
53%
Assessment of pharmacological treatment of COPD 66%
Provision of dietary advice for underweight/overweight
patients
66%
Advice on smoking cessation/reduction 32%
Preparation of appointments with other health
personnel
54%
Involvement of caregivers in the care plan 16%
Support for psychological problematics (e.g., anxiety,
identity, and relations)
51%
Support for social problematics (e.g., economy, work
situation, and housing)
12%
Note. The table lists the components provided for the patients
during the intervention.
COPD, chronic obstructive pulmonary disease.
V A L U E I N H E A L T H 2 1 ( 2 0 1 8 ) 2 3 9 – 2 4 7 241intervention created a heterogeneous utilization pattern among
participants. This was a reﬂection of both demand (i.e., individual
characteristics of participants) and supply (in the sense that
various services were available).
Measures
During the study, a large amount of data was collected, which
included measures of effects, costs, and use of particular services
and type of support from the case manager.
Effects
Both groups ﬁlled out questionnaires at baseline and after
12 months of participation. The following questionnaires were
included: the generic questionnaires the three-level EuroQol ﬁve-
dimensional questionnaire (EQ-5D-3L), the 12-item short-form
health survey (SF-12), and the Patient Activation Measure (PAM-
13) as well as the disease-speciﬁc questionnaire St George’s
Respiratory Questionnaire (SGRQ). The questionnaire that was
ﬁlled out at baseline covered the patients’ demographic, disease-
speciﬁc, and psychosocial status.
Costs
Costs were gathered alongside the RCT from the perspective of
the health care sector. The included costs were direct disease-
related costs in the primary health care sector (general practi-
tioner contacts), the secondary health care sector (inpatient and
outpatient hospital treatment), cost of community care (home
assistance and household cleaning, home nurse care, training,
and temporary stay at nursing home), costs for prescription
medication, and intervention costs (case manager salary, cost
for coaching course, and cost for driving in case of home visits
and overhead). Valuation of the case manager salary reﬂected the
time spent per patient, whereas ﬁxed costs for the intervention
were evenly distributed among intervention patients. All but
intervention costs were drawn from Danish registers by using
the patients’ unique identiﬁcation numbers. Costs related to trial
execution were not included in the analysis because they were
considered one-time costs. A thorough description of the valu-
ation of the applied costs and the change in resource use over the
course of treatment is given elsewhere [17].
Utilization of services
Besides an introduction to the disease and advice on incorpo-
ration of physical activities in daily life, which all patients
received, the case manager systematically registered the compo-
nents that were addressed for each patient during the interven-
tion while the RCT was carried out. The components and
associated rates provided for the patients during the trial are
presented in Table 1. Each component could be addressed more
than once during the intervention; that is, patients could, for
instance, receive psychological support several times during the
intervention period; nevertheless, data on this were not regis-
tered during the trial.
Statistical Analysis
Latent class analysis
Because the case management that was provided differed accord-
ing to patient needs and preferences, LCA was used to identify
whether there existed subgroups of patients in the intervention
group on the basis of eight registered measures of utilized
services. LCA is a latent variable model in which both the latent
variable and the observed variables for each latent class are
categorical [9]. In LCA, two types of parameters are estimated: 1)
latent class prevalence and 2) probabilities of individuals’responses on each observed variable for each latent class. The
latter forms the basis for interpretation and labeling of the latent
classes. LCA should ideally result in the identiﬁcation of a set of
homogeneous classes.
With the number of latent classes initially being unknown, a
series of LCA models holding an increasing number of classes
were ﬁtted to the data. To determine the optimal number of
classes, the bootstrapped likelihood ratio test (BLRT) was used to
test the null hypothesis of the current number of classes against
an alternative with one additional class [19]. A fundamental
assumption of LCA is that conditional on the latent variable,
the observed variables should be statistically unrelated to or
independent from each other [9]. To assess whether this assump-
tion was in fact met, the bivariate residuals were obtained. A
bivariate residual higher than 1.96 indicates signiﬁcance, mean-
ing that the assumption of conditional independence is not met.
A precise description of the model speciﬁcation can be found in
the Supplemental Materials found at http://dx.doi.org/10.1016/j.
jval.2017.08.001. In LCA it is not uncommon to identify several
models that ﬁt data adequately. The ﬁnal model selection should
be based on parsimony of the latent class model as well as on
interpretability of the latent classes [9]. Therefore, in addition to
the model-ﬁt statistics, the theoretical meanings of the identiﬁed
classes were considered. After the selection of the best-ﬁtting
model, baseline demographic, clinical, and economic character-
istics for each latent class were identiﬁed using descriptive
statistics such as the Student t test for continuous variables
and χ2 tests for categorical data. This was done to examine
whether the characteristics were in line with the labeling of the
latent classes.
Mplus version 7 (Muthén & Muthén, Los Angeles, California)
and Stata version 13 (StataCorp LLC, College Station, Texas) were
used for the calculations.Cost-effectiveness analysis
To examine the cost-effectiveness at the class level, classes
similar to the latent classes identiﬁed in the intervention group
needed to be identiﬁed for patients in the original control group.
There is no agreement in the literature on the procedure for
generating a control group for cost-effectiveness analysis of
heterogeneous groups. Here, this was achieved by using multi-
nomial logistic regression (MLR), which predicts the probabilities
Table 2 – Fit statistics for the Latent Class Analyses.
No. of classes BLRT Bivariate residuals 41.96
Two 0.0001 0
Three 0.6667 0
Four 0.1923 0
Five 0.6667 0
BLRT, bootstrapped likelihood ratio test.
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dependent variable (here, class afﬁliation), given a set of inde-
pendent variables. The model was controlled for all the baseline
variables the case manager knew of in her work with the
intervention group, which included age, sex, educational status,
employment status, smoking status, pack-years of cigarette
smoking [20], modiﬁed Medical Research Council dyspnea scale,
COPD airﬂow limitation according to guidelines [18], number of
comorbidities, baseline utility obtained by the EQ-5D-3L (total
score and the ﬁve dimensions), and baseline scores for the SGRQ
and PAM-13. Patients were assigned to the class with the highest
probability for afﬁliation.
Cost-effectiveness was examined by using cost-utility analy-
ses (CUAs), and incremental cost-effectiveness ratios (ICERs)
were calculated for each class. Quality-adjusted life-years
(QALYs) were calculated by linear interpolation of utility scores
obtained from the EQ-5D-3L between baseline and after 12
months. Patients dying during the follow-up period received an
EQ-5D-3L index score equal to the health state for death.
Incremental estimates of QALYs and costs were obtained using
a seemingly unrelated regression model [21], in which QALYs
were adjusted for baseline health-related quality of life (HRQOL)
and cost outcomes were adjusted for baseline total cost [22,23].
Uncertainty surrounding the point estimates of mean costs and
effects was assessed by probabilistic sensitivity analysis (PSA) by
drawing 10,000 trial simulations from a normal distribution. The
Cholesky decomposition was applied to obtain correlated draws.
The results from the sensitivity analyses were presented at cost-
effectiveness thresholds of £20,000 to £30,000, and jointly illus-
trated in a cost-effectiveness scatterplot.Results
Randomization allocated 74 patients to usual care and 76 patients to
the case management intervention. During the study period six
patients died, of which two died shortly after randomization and
before receiving any case management. These two intervention
patients were excluded from further analysis to enhance precision
of the CUA estimates [24]. An additional ﬁve patients were lost to
follow-up during the study period. Missing data were present in 2%
to 4% of the cases. Before assessing the cost-effectiveness, missing
data were estimated according to guidelines by using multiple
imputations assuming data were missing at random [25,26].
Model Selection
On the basis of the BLRT calculated for two-class to ﬁve-class
models, we decided on a three-class model. Neither of the
estimated models had issues with the assumption of conditional
independence as evidenced from Table 2. The probabilities for
class allocation ranged between 85% and 100%, with most
probabilities ranging between 99% and 100%.
Characteristics of the Classes
Latent class analysis
An overview of the three classes is presented in Table 3. Class 1
was the smallest class and contained 12% of the intervention
patients. The class was labeled the “psychologically care” class
because there was a 100% conditional probability that patients in
this class had received psychological support and support for
preparation of appointments with other health personnel during
the intervention. This class also had the highest probability of
having received social support and involvement of caregivers
compared with the other two classes. Nevertheless, the proba-
bility of having received advice on COPD exacerbation prevention
was 0. Class 2 contained 46% of the intervention patients and waslabeled the “extensive COPD care” class because patients in this
class had especially high probabilities of having received the
COPD-speciﬁc components of the intervention. Hence, there was
a 100% conditional probability that patients in class 2 had
received COPD exacerbation prevention and almost 100% condi-
tional probability that the patients had their COPD pharmaco-
logical treatment assessed. Class 3 consisted of 42% of the
intervention patients. The class was labeled the “limited COPD
care” class because this class was characterized by patients
having low probabilities for any of the eight components.Descriptive statistics
Upon formation of the LCA, the demographic, clinical, and economic
characteristics for each class were examined, the data of which are
presented in Table 4. The psychologically care class primarily
consisted of females and most of the patients had a bachelor’s or
master’s degree. The patients were all nonsmokers, had the lowest
rate of pack-years of cigarette smoking, and presented with equally
grouped stages of COPD. In the year before inclusion in the study, no
COPD-related hospital admissions were registered for this class, and
the patients received less COPD medicine compared with patients in
the other classes. The psychologically care class had the lowest total
health care cost in the year before inclusion, which was primarily
due to no hospital admission costs during the previous year. The
main cost driver was the use of community care. The low EQ-5D-3L
and SF-12 scores showed that the psychologically care class con-
tained highly vulnerable patients. This held against the low use of
COPD medicine, and the moderate SGRQ score indicated that some-
thing other than COPD might contribute to the patient’s state of
health. Although it could be speculated whether the patients suffered
more from, for example, depression, no data were registered that
could clarify it.
The extensive COPD care class contained a slight over-repre-
sentation of males and most of the patients had no education or
were lower educated. The class had the highest rate of current
smokers and smoking pack-years and presented with a worse
mean modiﬁed Medical Research Council score than did the other
two classes. More than 70% of the patients in the extensive COPD
care class had severe or very severe COPD, and the class did not
contain any patients with mild COPD. The class presented with
the lowest EQ-5D score and SGRQ scores for all parameters, and
scored additionally low for the SF-12 questionnaire. The class
received markedly more medicine than did the other classes,
and it presented with the highest mean total health care cost.
The baseline characteristics for the class supported the ﬁndings
from the LCA, because this class appeared to consist of patients
with more progressive COPD than did patients from the other
classes.
The limited COPD care class contained slightly more females,
and, similar to the extensive COPD care class, most of the
patients had no education or were lower educated. The limited
COPD care class predominantly consisted of patients with mod-
erate COPD (61%), and the class presented with considerably
better scores for EQ-5D-3L, SF-12, and SGRQ than did the other
classes, indicating better HRQOL and a lower burden of COPD.
Table 3 – Overview of classes.
Class and
prevalence
(%)
Components of case management
Disease-speciﬁc components Psychosocial components
COPD
exacerbation
prevention
COPD
pharmacological
treatment
Smoking
cessation
support
Nutritional
guidance
Preparation
of
appointments
Involvement
of caregivers
Psychological
support
Social
support
Psychologically
care class
(0.12)
0 0.47 0 0.95 1 0.22 1 0.22
Extensive COPD
care class
(0.46)
1 0.93 0.42 0.59 0.66 0.20 0.62 0.14
Limited COPD
care class
(0.42)
0.15 0.43 0.31 0.67 0.28 0.11 0.26 0.08
All (1.00) 0.66 0.53 0.32 0.66 0.54 0.16 0.51 0.12
Note. Entries show conditional probabilities of addressing the topic (columns) given class membership (rows).
COPD, chronic obstructive pulmonary disease.
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munity care were lower for patients in the limited COPD care
class, although a smaller proportion of patients experienced
hospital admissions.
Cost-Effectiveness of the Classes
Using MLR for construction of control groups with a reasonably
good result, three subgroups were identiﬁed in the control group
presenting with similar baseline characteristics as the classes in
the intervention group. The MLR resulted in a 100% match for the
intervention group, meaning that the regression model identiﬁed
the same class afﬁliation for the intervention group as did the
LCA. The identiﬁcation of three subgroups in the control group
using MLR was believed to be justiﬁable.
The CUAs resulted in three distinct results, which are presented
in Table 5. The psychologically care class had an incremental mean
total cost of £972 (95% conﬁdence interval [CI] −808 to 2750) per
patient for case management. In addition, the case-managed group
had an incremental loss of −0.0387 QALY/patient (95% CI −0.1455 to
0.0681), which altogether resulted in an ICER of −£25,085/QALY. The
PSA revealed that the trial simulations were scattered in the north-
west and northeast quadrants primarily, with most being scattered
in the northwest quadrant, indicating case management being
dominated by usual care (see Fig. 1). The probability of case
management being cost-effective for the psychologically care class
was as low as 10% to 12% at cost-effectiveness thresholds of £20,000
to £30,000/QALY. The form of case management that was applied
was therefore not deemed cost-effective. Nevertheless, the result
should be interpreted with great caution given the very small
sample size for this class.
The extensive COPD care class had an incremental mean total
cost of £1652 (95% CI −2725 to 6029) per patient for the case-
managed group. Case management resulted in a signiﬁcant QALY
gain of 0.0612 (95% CI 0.0219 to 0.1006) per patient. With an ICER
of £26,986/QALY gained, which is in between the threshold set by
the National Institute of Health and Care Excellence, the case
management that was applied for the extensive COPD care class
was cost-effective. Most of the trial simulations were scattered in
the northeast quadrant of the cost-effectiveness scatterplot,
which indicated the intervention being more effective but also
more costly than usual care. The PSA revealed large uncertainty
in the cost-effectiveness estimate with a probability of 43% to
53% for the intervention being cost-effective at thresholds of
£20,000 to £30,000/QALY.The limited COPD care class had a decreased incremental total
cost of −£471 (95% CI −1712 to 770) and an incremental QALY of
−0.0556 (95% CI −0.1192 to 0.0080) for the case-managed group.
This resulted in an ICER of £8470/QALY. The cost-effectiveness
scatterplot primarily contained trial simulations in the southwest
and northwest quadrants, with most of them being scattered in
the southwest quadrant, indicating case management being both
less expensive and less effective than usual care. Although being
cost-saving, it appears to be at the expense of the patients’
HRQOL if the applied form of case management was to be
implemented for this patient group. The probability of the
case management intervention being cost-effective at thresholds
of £20,000 to £30,000/QALY was decreasing with probabilities of
24-15%.
Because the classes consisted of different groups of patients
receiving different components of case management, the cost-
effectiveness results should be interpreted separately.Discussion
LCA is an emerging method in the evaluation of patient hetero-
geneity in health research [27–31]. This study is the ﬁrst to apply
the method to analyze the interaction between service provision
variability and patient heterogeneity in cost-effectiveness analy-
ses of complex interventions. First, LCA revealed variability in the
case management service that was provided during the trial for
each patient, because three distinct classes were detected. We
named these the psychologically care class, the extensive COPD
care class, and the limited COPD care class. Second, observable
baseline patient characteristics were examined across the
classes, and the characteristics were generally in line with the
class-speciﬁc features identiﬁed in the LCA. Third, highly dispa-
rate cost-effectiveness estimates were revealed for the three
classes as well as probability of cost-effectiveness.
Interventions tailored to patient needs and preferences and
with active involvement of the patient are increasingly popular.
Such complex interventions introduce various confounding var-
iables that need to be taken into account in an evaluation.
Researchers, however, typically treat variation and heterogeneity
as noise that should be actively suppressed to establish the
efﬁcacy of tests or procedures. When doing so, one risks giving
patients treatments that do not help or denying patients treat-
ments that would. In addition, research is often based on,
presented as, and funded using average point estimates.
Table 4 – Descriptive statistics for all treated patients by class.
Patients’ characteristic Class 1 (n ¼ 9) Class 2 (n ¼ 37) Class 3 (n ¼ 28) Total (N ¼ 74)
Baseline demographic characteristics
Age (y), mean ± SD 66.95 ± 9.67 68.79 8.62 69.86 7.94 68.97 ± 8.43
Sex, male, n (%) 3 (33.33) 21 (56.76) 12 (42.86) 36 (48.65)
Living alone, n (%) 4 (44.44) 11 (29.73) 13 (46.43) 28 (37.84)
Employed, n (%) 2 (22.22) 5 (13.51) 4 (14.29) 11 (14.86)
Educational level, n (%)
No education 2 (22.22) 15 (40.54) 14 (50.00) 31 (41.89)
Vocational education or academy profession degree 1 (11.11) 19 (51.35) 7 (25.00) 27 (36.49)
Bachelor’s and/or master’s degree 6 (66.67) 3 (8.11) 7 (25.00) 16 (21.62)
Baseline clinical measures
Comorbidities, n (%)
Diabetes – 4 (10.81) 3 (10.71) 7 (9.46)
Heart disease 6 (66.67) 21 (56.76) 19 (67.86) 46 (62.16)
Osteoporosis 2 (22.22) 7 (18.92) 5 (17.86) 14 (18.92)
Cancer 2 (22.22) 5 (13.51) 6 (21.43) 13 (17.57)
Current smoker, n (%) – 13 (35.14) 8 (28.57) 21 (28.37)
Pack-year, mean ± SD 21.65 ± 17.40 45.91 ± 18.42 33.31 ± 19.18 38.19 ± 20.24
mMRC, mean ± SD 1.88 ± 1.05 2.24 ± 0.72 1.75 ± 0.65 2.01 ± 0.77
Airﬂow limitation, n (%)
Mild (FEV1Z80%) 2 (22.22) – 1 (3.57) 3 (4.05)
Moderate (FEV1, 50%–79%) 2 (22.22) 11 (29.73) 17 (60.71) 30 (40.54)
Severe (FEV1, 30%–49%) 3 (33.33) 19 (51.35) 7 (25.00) 29 (39.19)
Very severe (FEV1,o 30%) 2 (22.22) 7 (18.92) 3 (10.71) 12 (16.22)
SGRQ, mean ± SD
Symptoms score 44.47 ± 32.01 57.66 ± 13.74 43.69 ± 22.44 50.77 ± 20.97
Activity score 57.49 ± 29.38 71.11 ± 19.17 49.03 ± 22.05 61.10 ± 23.75
Impact score 33.57 ± 25.40 37.43 ± 20.86 21.31 ± 17.68 30.86 ± 21.41
Total score 42.70 ± 26.79 51.18 ± 16.87 33.42 ± 17.68 43.43 ± 20.09
PAM-13, mean ± SD 60.68 ± 13.00 59.07 ± 11.92 60.42 ± 13.37 59.78 ± 12.46
EQ-5D, mean ± SD 0.71 ± 0.22 0.68 ± 0.24 0.89 ± 0.14 0.75 ± 0.22
SF-12, mean ± SD
Physical score 31.78 ± 13.98 34.29 ± 8.90 41.78 ± 10.51 36.68 ± 10.80
Mental score 51.57 ± 15.73 50.74 ± 12.50 58.18 ± 8.63 53.53 ± 12.07
Resource use 1 y before inclusion
Primary care (GP consultations)
Mean ± SD 8.33 ± 7.19 10.51 ± 8.17 9.25 ± 7.67 9.77 ± 7.81
Median (25%–75%) 8 (2–12) 8 (6–12) 7 (5–11) 8 (5–12)
Secondary care
COPD admissions
Mean ± SD – 0.43 ± 0.90 0.39 ± 1.52 0.36 ± 1.13
Median (25%–75%) – 0 (0–0) 0 (0–0) 0 (0–0)
COPD outpatient visits
Mean ± SD 1.00 ± 2.00 0.68 ± 1.08 0.21 ± 0.69 0.54 ± 1.13
Median (25%–75%) 0 (0–0) 0 (0–1) 0 (0–0) 0 (0–0)
Packages of prescribed COPD medicine
Mean ± SD 15.89 ± 14.25 32.98 ± 18.29 18.64 ± 17.80 25.45 ± 19.02
Median (25%–75%) 13 (5–20) 30 (20–38) 20 (2–26) 24 (13–33)
Hours of community care
Mean ± SD 59.06 ± 102.29 47.81 ± 123.65 26.02 ± 85.65 40.93 ± 107.47
Median (25%–75%) 0 (0–60) 0 (0–36) 0 (0–2) 0 (0–35)
Costs (£) 1 y before inclusion
Primary care, mean ± SD 508 ± 315 709 ± 508 831 ± 1226 731 ± 839
Secondary care, mean ± SD 316 ± 646 1432 ± 2648 1225 ± 4441 1218 ± 3305
COPD medicine, mean ± SD 607 ± 606 1047 ± 475 665 ± 573 849 ± 559
Community care, mean ± SD 1039 ± 1788 830 ± 2137 461 ± 1516 716 ± 1870
Total cost, mean ± SD 2469 ± 2113 4019 ± 4080 3182 ± 7295 3514 ± 5356
Note. Non-normally distributed variables are listed with both mean and median. SGRQ scores go from 0 (better health status) to 100 (worse
health status). PAM-13 scores are divided into four levels of activation: level 1, starting to take a role (score ≤47.0); level 2, building knowledge
and conﬁdence (score 47.1–55.1); level 3, taking action (score 55.2–67.0); and level 4, maintaining behaviors (score ≥67.1). SF-12 scores go from
0 (worse health status) to 100 (better health status).
COPD, chronic obstructive pulmonary disease; EQ-5D-3L, three-level version of the EuroQol ﬁve-dimensional questionnaire; FEV1,
forced expiratory volume in 1 minute; GP, general practitioner; mMRC, modiﬁed Medical Research Council; PAM-13, Patient Activation
Measure; SF-12, 12-item short-form health survey; SGRQ, St George’s Respiratory Questionnaire.
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Table 5 – Cost-effectiveness results at class level.
Class Incremental
cost (£)
(95% CI)
Incremental
QALY
(95% CI)
ICER
(£/QALY)
Cost-effectiveness plane
(%/quadrant)
Probability of being
cost-effective
at thresholds of
£20,000–£30,000/QALYNW NE SE SW
Psychological care 972 (−808 to 2752) −0.0387 (−0.1455 to 0.0681) −25,085 0.66 0.21 0.03 0.10 10%–12%
Extensive COPD care 1652 (−2725 to 6029) 0.0612 (0.0219 to 0.1006)* 26,986 0.00 0.76 0.24 0.00 43%–53%
Limited COPD care −471 (−1712 to 770) −0.0556 (−0.1192 to 0.0080) 8470 0.22 0.01 0.03 0.74 24%–15%
CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; ICER, incremental cost-effectiveness ratio; NE, northeast quadrant
(more cost and more effect); NW, northwest quadrant (more cost and less effect); QALY, quality-adjusted life-year; SE, southeast quadrant (less
cost and more effect); SW, southwest quadrant (less cost and less effect).
⁎ Signiﬁcant difference (P o 0.05).
Fig. 1 – The cost-effectiveness plane (A) and the cost-
effectiveness acceptability curve (B) at the class level.
Note. Part (A) illustrates the cost-effectiveness scatterplot of
case management vs. usual care with 10,000 simulations of
incremental costs and QALYs for each class. The cost-
effectiveness threshold of £20,000 is illustrated by the black
line running through (0.0) in the scatterplot. For the
extensive COPD class, 43% of the simulations fall under the
threshold line, indicating that case management is a cost-
effective strategy compared with usual care in 43% of the
simulations. For the psychologically care class and the
limited COPD care class, only 10% and 24% of the
simulations, respectively, fall under the threshold line. Part
(B) illustrates the probability of case management being
cost-effective at different cost-effectiveness thresholds as
compared with usual care at the class level. COPD, chronic
obstructive pulmonary disease; QALY, quality-adjusted life-
year.
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ment was evaluated in the group as a whole in accordance with
current practice, and when adjusting for the same covariates as
in the present article, the intervention resulted in an ICER of
£52,961/QALY gained [17]. The ﬁndings in this study, however,
indicate that “the average patient” does not exist, which illus-
trates the need for this to be addressed in an evaluation of
complex interventions. Albeit the result was associated with high
uncertainty, it appears that case management might be cost-
effective for the extensive COPD care class with an ICER of
£26,986/QALY gained assuming a threshold value of £30,000.
Hence, ignoring the interaction between variation in service
provision and patient heterogeneity, when this is in fact present,
could be costly both in monetary terms and in health gain.
Current health economic guidelines address patient hetero-
geneity by using different stratiﬁed analyses [3,4,32]. As described
earlier, traditional regression-based techniques for subgrouping
patients post hoc identify subgroups on the basis of the patient
characteristics associated with outcome; nevertheless, ﬁndings
from such analyses can be obscured when both supply-side
variation and demand-side heterogeneity are present, as was
the case in our analysis. The impact on cost-effectiveness of
using a traditional approach for subgroup analysis has been
assessed as part of a sensitivity analysis, and the results are
presented in the Supplemental Materials. Two subgroup analyses
have been conducted. The ﬁrst analysis addressed supply-side
variability, because subgroups were formed on the basis of
treatment intensity (number of components received). This
analysis did not demonstrate a correlation between treatment
intensity and cost-effectiveness. Demand-side heterogeneity was
addressed in the second analysis, because subgroups were
formed on the basis of severity of airﬂow limitation according
to the classiﬁcation provided by the Global Initiative for Chronic
Obstructive Lung Disease [33]. This analysis demonstrated that
case management was a dominant strategy when compared with
usual care in patients with severe airﬂow limitation, because it
was cost-saving at an additional QALY gain. Case management
would not be considered a cost-effective strategy in patients with
COPD with mild/moderate and very severe airﬂow limitation.
Although this is an interesting ﬁnding, the analysis does not
reveal anything about what was (and what should be) supplied
for patients with COPD with severe airﬂow limitation to obtain
this outcome, just as the analysis does not take potential
unobservable patient heterogeneity into account.
Contrary to the traditional approach for subgroup analysis,
LCA provides an opportunity to address supply-side variation and
unobservable demand-side heterogeneity simultaneously. LCA is
not driven by associations with an outcome but instead uses a
mixture of distributions to identify latent data structures. A
strength of LCA is that it, as opposed to traditional methods,
provides an overview of the latent patterns of heterogeneity that
V A L U E I N H E A L T H 2 1 ( 2 0 1 8 ) 2 3 9 – 2 4 7246is present within a sample, which can later be studied against a
range of outcomes [32]. LCA helped to identify the treatment
pattern that provided the best balance between considering all
patients to belong to the same group and considering all existing
treatment patterns to be a relevant subgroup on their own. All
patients being in one subgroup would have meant that the
provided case management originated from one underlying
distribution with scores from 0 to 8 (from no case management
components to all case management components). This would
have implied that it was not important how many and which
components of case management the individual patient received.
Instead, LCA enabled us to identify treatment patterns in the data
that best explained the latent data structure.
A three-class model was chosen as the optimal number of
classes on the basis of the BLRT as well as on the interpretability
of the model. Nevertheless, to assess the sensitivity of the cost-
effectiveness results to the deﬁnition of classes, a sensitivity
analysis had been conducted using a two-class and a four-class
model. The results hereof are presented in the Supplemental
Materials. The extensive COPD care class was likewise identiﬁed
in the two-class model and presented with a similar cost-
effective result as in the three-class model, which supports the
ﬁnding on cost-effectiveness for this subgroup. The four-class
model, however, did not result in the identiﬁcation of distinctive
and meaningful subgroups.
When conducting research on complex interventions, much
thought needs to be given to proper evaluation already at the
design phase of the intervention. From the perspective of eco-
nomic evaluation, it is important to determine the mechanisms
of a complex intervention that may inﬂuence both outcomes and
costs. We emphasize strongly that, in addition to traditional
baseline and follow-up measures on patient characteristics,
effects, and costs, appropriate process data on service utilization
need to be collected. Such process measures should at a mini-
mum reﬂect which patients received which components of the
intervention. Without doing so it becomes difﬁcult, if not impos-
sible, to examine what is actually done under the heading of “the
intervention” and link it with outcome. In addition, measures on
dosage of the intervention, such as amount, frequency, and
duration, could be considered collected, although the potential
gain of such detailed recording should be balanced against the
associated use of resources.
As with any research, this study also had limitations. Keeping
the total sample size in mind, there is a risk that small but
meaningful subgroups have gone undetected. As a consequence,
the ﬁndings are merely hypothesis-generating and should be
validated in future research. The ﬁndings from the LCA rely on
the case manager’s ability to correctly identify the best treatment
protocol for each patient. It cannot be precluded whether the
patients would have beneﬁted further from receiving more or all
components of the intervention. Nevertheless, the fact that the
same features identiﬁed in the LCA could be observed in the
baseline characteristics supports her skills as a case manager. In
addition, only one case manager was afﬁliated with the trial, and
presently it cannot be ruled out whether other classes would
have formed if the intervention had been provided by another
case manager. The use of LCA in health care decision making is
not straightforward because of a number of potential issues.
Because LCA is more exploratory in nature than subgroups
identiﬁed using associations with a clinical outcome, it can lead
to subgroups that are difﬁcult to interpret [32]. Future studies
should therefore examine whether other demographic, clinical,
or behavioral factors can more readily distinguish between the
classes and link ﬁndings with outcome. The LCA disentangled
patient heterogeneity in respect of process measures on received
case management components. Whether the same latent classes
would have been identiﬁed if the analysis had been conductedusing other process measures (e.g., treatment intensity) remains
to be examined. The process measures were obviously not
registered for the control group patients. Instead, counterfactuals
for each latent class were estimated by MLR using observable
patient baseline characteristics. The patients’ baseline character-
istics for each counterfactual revealed overall consistency with
the patients’ baseline characteristics identiﬁed for the corre-
sponding latent classes in the intervention group. It is believed
that the estimated counterfactuals are justiﬁable. Nevertheless,
because falsely estimated counterfactuals can substantially
impact on estimations of cost-effectiveness, it should be exam-
ined in future research whether there are other more appropriate
methodologies for generating control groups in the analysis of
heterogeneity.
We believe that our proposed method provides a means to
uncover some of the complexity of complex interventions,
because it can provide a deeper understanding of what works
for whom. It is conceivable that it can be applied both to full-scale
RCTs and for pretesting in pilot trials, with the latter of the two
informing researchers about potential classes and their interven-
tion contents to be tested in subsequent RCTs. In time, it may
serve as a tool to enable more appropriate targeting of complex
care strategies to those patients expected to show the strongest
response. Nevertheless, the proposed method calls for further
research to determine its applicability in economic evaluation,
and, in particular, its usefulness for health care decision making.Conclusions
By using LCA on process measures of service utilization, three
subgroups of COPD patients with signiﬁcant differences in
patient characteristics and estimates of cost-effectiveness were
identiﬁed. This illustrates the importance of investigating
patterns of interaction between supply-side variation and
demand-side heterogeneity when evaluating complex interven-
tions targeted to individual patient needs, preferences, and
health behaviors. In this context, we propose the use of LCA
and recommend that further research be conducted in the ﬁeld of
economic evaluation of complex interventions.
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